FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947223730> ?p ?o ?g. }

• W2947223730 endingPage "3171" @default.
• W2947223730 startingPage "3164" @default.
• W2947223730 abstract "Certain patients with intermediate-risk prostate cancer (PCa) may be appropriate candidates for active surveillance (AS). In the current study, the authors sought to characterize AS use and early mortality outcomes for patients with intermediate-risk PCa in the United States.The novel Surveillance, Epidemiology, and End Results Active Surveillance/Watchful Waiting database identified 52,940 men diagnosed with National Comprehensive Cancer Network intermediate-risk PCa (cT2b-c, Gleason score of 7, or a prostate-specific antigen level of 10-20 ng/mL) and actively managed (AS, radiotherapy, or radical prostatectomy) from 2010 through 2015. The Cuzick test assessed AS time trends, and logistic multivariable regression characterized features associated with AS. Fine-Gray and Cox modeling determined PCa-specific mortality (PCSM) and overall survival, respectively.The rate of AS increased from 3.7% in 2010 to 7.3% in 2015, and from 7.2% to 11.7% among men aged ≥70 years. Among men with favorable and unfavorable intermediate-risk disease, the use of AS increased from 7.2% to 14.9% and from 2.2% to 3.8%, respectively (all P value for trend, <.001). The mean age of those patients managed with AS decreased from 69.9 years to 67.9 years (P = .0004). Factors found to be associated with AS included favorable risk disease; black race; higher socioeconomic status; older age; and diagnosis in the West, Northwest, or Midwest regions of the United States. The 5-year PCSM rate was comparable to AS versus treatment among patients with low-risk and favorable intermediate-risk disease, but was worse with AS among those with unfavorable intermediate-risk disease (PCSM, 1.3% vs 0.5%; adjusted hazard ratio, 2.48 [95% CI, 1.11-5.50; P = .026]) and intermediate-risk disease overall (PCSM, 1.1% vs 0.4%; adjusted hazard ratio, 2.34 [95% CI, 1.25-4.37; P = .008]).The use of AS for patients with intermediate-risk PCa is increasing across the United States, particularly for older men and those with favorable intermediate-risk disease. Early estimates of cancer-specific and overall mortality rates are low with AS, although significantly higher compared with treatment." @default.
• W2947223730 created "2019-06-07" @default.
• W2947223730 creator A5001077235 @default.
• W2947223730 creator A5008974264 @default.
• W2947223730 creator A5011067188 @default.
• W2947223730 creator A5015096941 @default.
• W2947223730 creator A5018608069 @default.
• W2947223730 creator A5044221282 @default.
• W2947223730 creator A5048397052 @default.
• W2947223730 creator A5073123534 @default.
• W2947223730 date "2019-05-31" @default.
• W2947223730 modified "2023-10-16" @default.
• W2947223730 title "Use and early mortality outcomes of active surveillance in patients with intermediate‐risk prostate cancer" @default.
• W2947223730 cites W1591554783 @default.
• W2947223730 cites W1831945879 @default.
• W2947223730 cites W1971211622 @default.
• W2947223730 cites W1989403098 @default.
• W2947223730 cites W2015712245 @default.
• W2947223730 cites W2070912263 @default.
• W2947223730 cites W2106869018 @default.
• W2947223730 cites W2110569728 @default.
• W2947223730 cites W2110733906 @default.
• W2947223730 cites W2134793522 @default.
• W2947223730 cites W2138977598 @default.
• W2947223730 cites W2141198296 @default.
• W2947223730 cites W2148497849 @default.
• W2947223730 cites W2156928739 @default.
• W2947223730 cites W2163144362 @default.
• W2947223730 cites W2291813266 @default.
• W2947223730 cites W2295402589 @default.
• W2947223730 cites W2513151665 @default.
• W2947223730 cites W2514067509 @default.
• W2947223730 cites W2519027667 @default.
• W2947223730 cites W2520876570 @default.
• W2947223730 cites W2523396458 @default.
• W2947223730 cites W2601473067 @default.
• W2947223730 cites W2615697870 @default.
• W2947223730 cites W2767580925 @default.
• W2947223730 cites W2769578203 @default.
• W2947223730 cites W2781525129 @default.
• W2947223730 cites W2786117166 @default.
• W2947223730 cites W2804681057 @default.
• W2947223730 doi "https://doi.org/10.1002/cncr.32202" @default.
• W2947223730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31150125" @default.
• W2947223730 hasPublicationYear "2019" @default.
• W2947223730 type Work @default.
• W2947223730 sameAs 2947223730 @default.
• W2947223730 citedByCount "29" @default.
• W2947223730 countsByYear W29472237302019 @default.
• W2947223730 countsByYear W29472237302020 @default.
• W2947223730 countsByYear W29472237302021 @default.
• W2947223730 countsByYear W29472237302022 @default.
• W2947223730 countsByYear W29472237302023 @default.
• W2947223730 crossrefType "journal-article" @default.
• W2947223730 hasAuthorship W2947223730A5001077235 @default.
• W2947223730 hasAuthorship W2947223730A5008974264 @default.
• W2947223730 hasAuthorship W2947223730A5011067188 @default.
• W2947223730 hasAuthorship W2947223730A5015096941 @default.
• W2947223730 hasAuthorship W2947223730A5018608069 @default.
• W2947223730 hasAuthorship W2947223730A5044221282 @default.
• W2947223730 hasAuthorship W2947223730A5048397052 @default.
• W2947223730 hasAuthorship W2947223730A5073123534 @default.
• W2947223730 hasBestOaLocation W29472237301 @default.
• W2947223730 hasConcept C107130276 @default.
• W2947223730 hasConcept C121608353 @default.
• W2947223730 hasConcept C126322002 @default.
• W2947223730 hasConcept C144024400 @default.
• W2947223730 hasConcept C147077947 @default.
• W2947223730 hasConcept C149923435 @default.
• W2947223730 hasConcept C151956035 @default.
• W2947223730 hasConcept C2776141087 @default.
• W2947223730 hasConcept C2778527826 @default.
• W2947223730 hasConcept C2779134260 @default.
• W2947223730 hasConcept C2779391198 @default.
• W2947223730 hasConcept C2779466945 @default.
• W2947223730 hasConcept C2780192828 @default.
• W2947223730 hasConcept C2781406297 @default.
• W2947223730 hasConcept C2908647359 @default.
• W2947223730 hasConcept C29456083 @default.
• W2947223730 hasConcept C50382708 @default.
• W2947223730 hasConcept C71924100 @default.
• W2947223730 hasConcept C99454951 @default.
• W2947223730 hasConceptScore W2947223730C107130276 @default.
• W2947223730 hasConceptScore W2947223730C121608353 @default.
• W2947223730 hasConceptScore W2947223730C126322002 @default.
• W2947223730 hasConceptScore W2947223730C144024400 @default.
• W2947223730 hasConceptScore W2947223730C147077947 @default.
• W2947223730 hasConceptScore W2947223730C149923435 @default.
• W2947223730 hasConceptScore W2947223730C151956035 @default.
• W2947223730 hasConceptScore W2947223730C2776141087 @default.
• W2947223730 hasConceptScore W2947223730C2778527826 @default.
• W2947223730 hasConceptScore W2947223730C2779134260 @default.
• W2947223730 hasConceptScore W2947223730C2779391198 @default.
• W2947223730 hasConceptScore W2947223730C2779466945 @default.
• W2947223730 hasConceptScore W2947223730C2780192828 @default.
• W2947223730 hasConceptScore W2947223730C2781406297 @default.
• W2947223730 hasConceptScore W2947223730C2908647359 @default.
• W2947223730 hasConceptScore W2947223730C29456083 @default.

• next